NCT01551680 2025-02-13
RAPIBE
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1 Terminated
Clinical Trials
17 trialsNCT00687765 2022-09-14
Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma
Sanofi
Phase 1/2 Completed
NCT01593228 2017-09-19
Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial
Sanofi
Phase 3 Completed
NCT01204125 2017-03-22
SOLTI NEOPARP
Sanofi
Phase 2 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00813956 2016-03-17
A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT01033123 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT01033292 2016-03-17
A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Sanofi
Phase 2 Completed
NCT01082549 2016-03-17
ECLIPSE
Sanofi
Phase 3 Completed
NCT01455532 2014-10-22
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
Sanofi
Phase 1 Completed
NCT01045304 2014-01-14
Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer
Sanofi
Phase 2 Completed
NCT00677079 2013-10-01
Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Sanofi
Phase 2 Completed
NCT01086254 2013-09-24
SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer
Sanofi
Phase 2 Completed
NCT01161836 2013-09-24
An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
Sanofi
Phase 1 Completed
NCT00938652 2013-09-19
A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
Sanofi
Phase 3 Completed
NCT01213381 2013-05-24
Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00540358 2012-12-28
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
Sanofi
Phase 2 Completed